)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Galderma Group
Galderma Group (GALD) investor relations material
Galderma Group Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary22 Oct, 2026
Executive summary
9M 2026 net sales reached $4,765M, up 25.1% YoY at constant currency (CC) and 27.5% reported; Q3 sales grew 26.0% CC.
Double-digit growth spanned all three product categories, led by Therapeutic Dermatology, Dermatological Skincare and Neuromodulators.
FY26 sales growth guidance increased to 22.5%-23.5% CC; ~26% CC Core EBITDA margin guidance was maintained.
Agreed to acquire ZO Skin Health, adding a physician-dispensed skincare platform; renewed growth is targeted from 2028.
Financial highlights
Q3 net sales were $1,632M, up 26.0% CC and 26.6% reported YoY.
9M U.S. sales rose 34.7% CC to $2,130M; International sales increased 18.0% CC to $2,636M.
Volume was the primary growth driver, supported by favorable mix, positive net pricing and consumer demand ahead of expectations.
Outlook and guidance
FY26 net sales growth guidance raised from 19%-21% to 22.5%-23.5% CC; Core EBITDA margin guidance remains ~26% CC.
Guidance excludes potential ZO Skin Health acquisition effects and assumes a 15% U.S. tariff on imported product value, with stated product and manufacturing exceptions.
Fillers & Biostimulators FY growth is expected broadly in line with 9M CC growth; injectable aesthetics growth is expected at 12%-13% CC.
Nemluvio is on track to exceed $1B global net sales in FY26; mature Therapeutic Dermatology is expected to grow mid-single digits CC.
Q4 comparisons include Nemluvio's Q4 2025 run-rate step-up and lower Brazil channel inventory ahead of January 2027 tax reform.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Galderma Group
- H1 2026 net sales surged 24.6% to $3.134B, driving a raised full-year growth outlook.GALD
Q2 2026 - Q1 2026 net sales surged 25.5% to $1.473B, with strong growth and guidance reaffirmed.GALDQ1 2026 TU
- Record sales and profit growth in 2025, with strong launches and raised guidance for 2026.GALDQ4 2025
- Transformed into a global dermatology leader with strong growth, innovation, and market expansion.GALDInvestor presentation
- L'Oréal acquires 10% stake and forms R&D partnership to drive dermatology innovation.GALDPartnership
- Record net sales and double-digit growth in aesthetics and skincare drive narrowed guidance.GALDQ3 2024 TU
- Record H1 2024 sales, margin expansion, and deleveraging drive upgraded full-year outlook.GALDH1 2024
- Record Q1 sales and strong launches drive confidence in double-digit 2025 growth targets.GALDQ1 2025 TU
- Record sales and EBITDA growth in 2024, with strong outlook and margin expansion ahead.GALDQ4 2024
Next Galderma Group earnings date
J.P. Morgan European Healthcare CEO Call Series24 Nov, 2026
Galderma Group
Next Galderma Group earnings date
J.P. Morgan European Healthcare CEO Call Series24 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Galderma Group AG, based in Zug, Switzerland, is a global dermatology company. It is committed exclusively to the field of dermatological care, encompassing a wide range of products and treatments across three main areas: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Galderma's offerings include widely recognized brands and solutions aimed at enhancing skin health for consumers and patients, supported by robust research and development efforts. The company is headquartered in Zug, Switzerland, and its shares are listed on the SIX Swiss Exchange.